Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | FER | P16591 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HK1 | P19367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311994 | 0.87 | LRRK2 (0.58) | AHRPDK2PDGFRAFERLTK | |
| SCHEMBL14084317 | 0.85 | TDP2 (0.61) | AHRPDK2PDGFRAFERLTK | |
| SCHEMBL30785257 | 0.81 | AHR (0.50) | AHRPDK2BCHECES1KDM4E | |
| SCHEMBL30785241 | 0.81 | ALDH1A1 (0.52) | AHRPDK2PDGFRAACVR1LRRK2 | |
| SCHEMBL2810679 | 0.81 | CDK2 (0.45) | AHRPDK2PDGFRAFERLTK | |
| Valine SCHEMBL8573024 | 0.80 | AHR (0.40) | AHRPDK2PDGFRAFERLTK | |
| SCHEMBL1050699 | 0.79 | AHR (0.57) | AHRPDK2PDGFRAFERLTK | |
| SCHEMBL1816980 | 0.79 | AHR (0.63) | AHRPDK2PDGFRAFERLTK | |
| SCHEMBL30785269 | 0.79 | AHR (0.49) | AHRPDK2ACVR1LRRK2BCHE | |
| SCHEMBL2809390 | 0.78 | CYP1A2 (0.59) | AHRPDK2BCHECES1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117402116-A | Process for the preparation of dibenzoazepine compounds and their use as interferon activator protein agonists | 河北中科金辉药业有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-115558121-A | Porous coordination polymer, preparation method thereof and separation method of isotopologue | 华南理工大学 | 2023-01-03 | — | — | CN | claimed |
| US-9346760-B2 | Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof | JUBILANT LIFE SCIENCES LIMITED (IN) | 2016-05-24 | — | — | US | claimed |
| US-20130345198-A1 | PROCESS FOR THE PREPARATION OF (S)-(+)- OR (R)-(-)-10-HYDROXY DIHYDRODIBENZ[B,F]AZEPINES BY ENANTIOSELECTIVE REDUCTION OF 10,11-DIHYDRO-10-OXO-5H-DIBENZ[B,F]AZEPINES AND POLYMORPHS THEREOF | JUBILANT LIFE SCIENCES LIMITED (IN) | 2013-12-26 | — | — | US | claimed |
| CN-119264051-A | Preparation method of key intermediate of dibenzoazepine medicines and intermediate thereof | 浙江中科创越药业有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4348727-A1 | AN ORGANIC ELECTROLUMINESCENT DEVICE AND A COMPOUND FOR USE THEREIN | Novaled GmbH (DE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117402116-A | Process for the preparation of dibenzoazepine compounds and their use as interferon activator protein agonists | 河北中科金辉药业有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-11782347-B2 | Composition for forming organic film, patterning process, and polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-10 | — | — | US | disclosed |
| US-11782347-B2 | Composition for forming organic film, patterning process, and polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20230277551-A1 | ANTIBACTERIAL CHEMICAL COMPOUND, ITS MANUFACTURING METHOD AND ITS USE THEREOF | NATIONAL YANG MING CHIAO TUNG UNIVERSITY (TW) | 2023-09-07 | — | — | US | disclosed |
| CN-115558121-B | Porous coordination polymer and preparation and separation method for isotopologues | 华南理工大学 | 2023-06-20 | — | — | CN | disclosed |
| CN-115558121-A | Porous coordination polymer, preparation method thereof and separation method of isotopologue | 华南理工大学 | 2023-01-03 | — | — | CN | disclosed |
| WO-2008012837-A1 | PROCESS FOR PRODUCING 10-OXO-L10, 11-DIHYDR0-5H-DIBENZ [B, F] AZEPINE-5-CARBOXAMIDE STARTING FROM 5-CYANOIMINOSTILBENE | JUBILANT ORGANOSYS LIMITED (IN) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007141798-A1 | PROCESS FOR PRODUCING OXCARBAZEPINE VIA AN 11-ALKOXY-10-HALO-DIHYDROIMINOSTILBENE INTERMEDIATE | JUBILANT ORGANOSYS LIMITED (IN) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007008576-A2 | OXCARBAZEPINE FORMULATION | TARO PHARMACEUTICALS U.S.A., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| US-7125987-B2 | Process for the preparation of oxcarbazepine and related intermediates | APOTEX PHARMACHEM INC. (CA) | 2006-10-24 | — | — | US | disclosed |
| US-20050282797-A1 | Process for the preparation of oxcarbazepine and related intermediates | APOTEX PHARMACHEM INC. | 2005-12-22 | — | — | US | disclosed |
| US-6235730-B1 | ANTICHOLESTEROL AGENT, ANTILIPEMIC AGENT | JAPAN TOBACCO, INC. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0970954-A1 | 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME | JAPAN TOBACCO INC. (JP) | 2000-01-12 | — | — | EP | disclosed |
| US-5808058-A | Process for the preparation of 10-OXO-10, 11-dihydro-5H-dibenz (b,f) azepin-5-carboxamide | TRIFARMA S.R.L. (IT) | 1998-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282797-A1 | Process for the preparation of oxcarbazepine and related intermediates | OXER1, OGDH, CYP4B1 | AHR 1393/4885PDK2 494/4885PDGFRA 4251/4885 |
| US-20230277551-A1 | ANTIBACTERIAL CHEMICAL COMPOUND, ITS MANUFACTURING METHOD AND ITS USE THEREOF | VIP, MRPL21, GSDMD | AHR 2592/4885PDK2 4491/4885PDGFRA 2224/4885 |
| US-20130345198-A1 | PROCESS FOR THE PREPARATION OF (S)-(+)- OR (R)-(-)-10-HYDROXY DIHYDRODIBENZ[B,F]AZEPINES BY ENANTIOSELECTIVE REDUCTION OF 10,11-DIHYDRO-10-OXO-5H-DIBENZ[B,F]AZEPINES AND POLYMORPHS THEREOF | CYP2F1, CYP4B1, CYP3A4 | AHR 489/4885PDK2 2268/4885PDGFRA 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.